MediciNova, Inc.

Healthcare · Biotechnology · United States

Last price 1.4 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 68.91M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, and glioblastoma, as well as prevention of acute res...